A Multicenter RCT Study of 3DV Technology in the Diagnosis and Treatment of PLC
NCT05118451 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 420
Last updated 2022-02-10
Summary
Primary liver cancer is the most common malignant tumor of the liver. Radical surgery is the preferred treatment, but its 5-year recurrence rate is as high as 70%, which is often associated with incomplete surgical resection and residual tumor. Since the 21st century, with the rapid development of surgery and new science and technology, the diagnosis and treatment of liver diseases have been closely linked with imaging diagnostics, biomedical engineering, molecular imaging technology, computer science and other interdisciplinary subjects. Three-dimensional (3D) visualization technology is one of the emerging auxiliary diagnosis and treatment methods. It plays an important role in accurate diagnosis, surgical planning and surgical navigation of primary liver cancer, and can effectively improve the success rate of surgery and reduce the incidence of postoperative complications. Its diagnostic and treatment value in primary liver cancer is mainly reflected in :(1) to clarify the spatial location relationship of abdominal space occupying lesions, understand the relationship between space occupying lesions and surrounding tissues, important blood vessels and cavities, judge tumor resectable, and make preoperative planning for tumor classification and surgical resection scope. (2) Calculation of individual liver segmentation and liver volume based on the topological relationship of blood flow 4. 3D simulation software was used to automatically calculate the resectioned liver volume and residual liver volume with statistical correlation, which was helpful to judge the probability of liver failure after liver cancer. (3) Variation of hepatic artery, portal vein and bile duct can be found, and the variation of duct can be evaluated by three-dimensional model, including whether there is contact, length of contact, whether there is stenosis in lumen, etc., especially the resectable ability of tumor patients can be evaluated by 3D and real-time dynamic navigation during surgery.
Conditions
- Primary Liver Cancers
Interventions
- PROCEDURE
-
3 d visualization technology
3D visualization technology refers to the conversion of 2d imaging data such as CT and MR into 3D stereoscopic images through computer calculation, analysis and reconstruction, visually separating the shapes and spatial distribution features of targets such as liver, blood vessels and tumors directly, accurately and quickly to present three-dimensional views. Combined with transparency, rotation, scaling and measurement techniques, real-time and interactive 3D dynamic analysis of 3d visual model is carried out. In addition, the computer was used to simulate the operation, and the feasible surgical plan was discussed. The best surgical plan was selected based on the patient's individual data.
Sponsors & Collaborators
-
Zhujiang Hospital
lead OTHER
Principal Investigators
-
Chihua Fang, MD · Zhujiang Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 66 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-07-01
- Primary Completion
- 2025-06-30
- Completion
- 2025-06-30
Countries
- China
Study Locations
More Related Trials
-
Safety and Clinical Efficacy of Histotripsy for Liver Cancers Adjacent to Major Intrahepatic Vessels
NCT07063771 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Stereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCC
NCT05433701 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.
NCT06311916 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Evaluation of Stereotactic Radiosurgery For Liver Malignancies
NCT00230347 ·Status: COMPLETED ·Phase: PHASE1
-
The Overall Survival of Patients With Unresectable HCC in Real-life
NCT03612726 ·Status: RECRUITING
-
Cytokine Change in Hepatocellular Carcinoma Treated by Thermal Ablation
NCT04555265 ·Status: COMPLETED ·Phase: NA
-
Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma
NCT03732547 ·Status: UNKNOWN ·Phase: PHASE2
-
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
NCT05250843 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
NCT05701436 ·Status: RECRUITING ·Phase: PHASE3
-
Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer
NCT05160740 ·Status: RECRUITING ·Phase: NA
-
TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma
NCT01833286 ·Status: UNKNOWN ·Phase: PHASE3
-
Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid
NCT06699524 ·Status: ACTIVE_NOT_RECRUITING
-
Accuracy Evaluation of Artificial Intelligence Assisted Liver Tumor Ablation Path Planning
NCT05161624 ·Status: UNKNOWN
-
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
NCT06420440 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
NCT05281926 ·Status: UNKNOWN ·Phase: PHASE1
-
PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial
NCT04814043 ·Status: UNKNOWN ·Phase: PHASE2
-
Standard Treatments of Very-early Stage Hepatocellular Carcinoma
NCT02728193 ·Status: COMPLETED ·Phase: NA
-
Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy
NCT04466124 ·Status: ENROLLING_BY_INVITATION
-
The Safety and Efficacy of Irreversible Electroporation for the Treatment of Perivascular Liver Cancers
NCT07214363 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer
NCT05371873 ·Status: UNKNOWN
-
Study of Liver Resection With Versus Without Hepatic Inflow Occlusion for the HBV-related HCC
NCT02563158 ·Status: UNKNOWN ·Phase: NA
-
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
NCT07131501 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer
NCT05660213 ·Status: NOT_YET_RECRUITING
-
Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media
NCT01563484 ·Status: UNKNOWN
-
Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm
NCT01825824 ·Status: UNKNOWN ·Phase: PHASE2